Allergies
AIM-Quoted Verona Pharma Progresses Anti-Asthma Drug Studies
Published in Drug Law Weekly, November 20th, 2007
The Company's novel anti-asthmatic compound, RPL554, is now entering a second 28-day experimental inhalation toxicology study in another species in order to demonstrate safety, before moving onto the proof of concept clinical trials early next year.
RPL554 is a long-acting bronchodilator/anti-inflammatory molecule being developed to treat hay fever (rhinitis), asthma and chronic obstructive pulmonary disease. A significant feature of RPL554 is that it does not use steroids or...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Law Weekly
Source: Drug Law Weekly (2007-11-20)
More Articles from Drug Law Weekly
- Artificial Grafts
Phoenix Hospital and Two Doctors' Groups to Pay U.S. $6.7 Million to Settle False Claims Act Allegations - ARYx Therapeutics, Inc.
ARYx Therapeutics, Inc. Announces Pricing of its Initial Public Offering - Biotechnology
Influential Health Care Companies to Present at 19th Annual Piper Jaffray Health Care Conference - Biotechnology Business
Biovail Enters into Development Agreement - Breast Implants
Heart Bypass Surgery Drug Causing Kidney/Renal Failure Suspended; Anapol Schwartz Attorney -- Representing Victims -- Says Situation Could Be Next Baycol - Cardiovascular Disease
Arizona Heart Hospital Reaches Settlement Regarding Clinical Research Matter - More from this issue of Drug Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
